Comparison of efficacy of alpha-glucosidase inhibitors in combination with dipeptidyl-peptidase-4 inhibitor (alogliptin) by continuous glucose monitoring between type 2 diabetic patients

Comparison of efficacy of alpha-glucosidase inhibitors in combination with dipeptidyl-peptidase-4 inhibitor (alogliptin) by continuous glucose monitoring between type 2 diabetic patients - comparison of efficacy of alpha-glucosidase inhibitors in combination with alogliptin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013135

Enrollment

Registered

2014-02-11

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

voglibose miglitol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All subjects presented with postprandial hyperglycemia in spite of administration of alogliptin (25mg) for more than 1 week. Participants provided their informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients using insulin therapy, those who were or may have been pregnant, and those with severe liver dysfunction (AST and ALT: 3 times the normal levels) were excluded.

Design outcomes

Primary

Measure	Time frame
The primary outcome measure used was SD of glucose and this was compared between the alpha-GIs (both being used in combination with alogliptin)	—

Countries

Japan

Contacts

Public ContactAkira Kurozumi

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

akira@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026